Clinical Trial Update: NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial of NY-ESO-1 vaccine combined with ipilimumab in unresectable or metastatic melanoma was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• NY-ESO-1 vaccine
• ipilimumab (ipilimumab)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Unresectable or Metastatic Melanoma | Phase 1 | Status: TERMINATED | Results posted: 2018-11-30